维普中文期刊产品整合服务
20篇 您的检索式:作者名="BLOUIN RA"
    题名 作者 年代 出处 被引量
1Pharmacokinetic considerations in obesity显示文摘Blouin RA Warren GW 1999J Pharm Sci1999,88,1:1
2Fleroxaxcin pharmacokinetics in patients with liver cirrhosis显示文摘Blouin RA Hamecin BA Smith DA 1992Antimicrob Agents Chemother1992,36,3:1
3Fleroxacin pharmacokinetics in patients with liver cirrhosis显示文摘Blouin RA Hamecin BA Smith DA 1992Antimicrob Agents Chemother1992,36,3:1
42,4, 4'-trichlorobiphenyl increases STATS transcriptional activity显示文摘Oakley GG Roe AL Blouin RA 2001Mol Carcinog2001,30,4:1
5Roles of innovation in education delivery显示文摘Blouin RA Riffee WH Robinson ET 2009Am J Pharm Educ2009,111,:1
6The protein binding of phenytoin,propranolol,diazepam,and AL01576(an aldose reductase inhibitor)in human and rat diabetic serum显示文摘Mc Namara PJ Blouin RA Brazzell RK 1988Pharm Res1988,5,5:1
7Vancomycin pharmacoki-netics in normal and morbidly obese subjects显示文摘Blouin RA Bauer LA Miller DD 1982Antimicrob AgentsChemother1982,21,:1
8The pharmacoki- netics of oral isradipine in normal volunteers显示文摘CLIFTON GD BLOUIN RA DILEA C 1988J Clin Pharma- col1988,28,1:1
9Vaneomyein pharma cokineties on normal and morbidly obese subjeets显示文摘Blouin RA Bauer LA Miller DD et aZ 1982Antimi- crob Agents Chemother1982,21,:1
10Maintenace of previously controlled intraocular pressure patients with glaucoma or ocular hypertension:comparision of four regiments of methazolamide显示文摘Foster TS Kielar RA Blouin RA 1989Glaucoma1989,11,:1
11Vancomyein pharmaeoki- neties in normal and morbidly obese subjects显示文摘Blouin RA Bauer LA Miller DD 1982Antimicrob Agents Che- mother1982,21,4:1
12Vancomycin phar- macokinetics in normal and morbidly obese subjects显示文摘Blouin RA Bauer LA Miller DD 1982An- timicrob Agents Chemother1982,21,4:1
13Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease显示文摘Van Ess PJ Pedersen WA Culmsee C Mattson MP Blouin RA 2002J Neurochem2002,80,4:1
14The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism : screening costs and influence on clinical outcomes in psychiatry显示文摘Chen S Chou WH Blouin RA 1996Clin Pharmacol Ther1996,60,5:1
15Pharmacokinetic considerations in obesity显示文摘Blouin RA Warren GW 1999Journal of Pharmaceutical Sciences1999,88,1:1
16Roles of Innovation in Education Delivery显示文摘Blouin RA Riffee WH Robinson ET 2009Am J Pharm Educ2009,73,8:1
17Characterization of nuclear protein binding(AP- 1, GR, and STAT) in the genetically obese(fa/fa)zucker rat显示文摘Roe AL Howard G Blouin RA 1998Life Sci1998,63,15:1
18The cytochrome P450 2D6(CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry 显示文摘Chen S Chou WH Blouin RA 1996Clin Pharmacol Ther1996,60,:1
19Phenytoin-dexamethasone interaction : a previously unreported observation显示文摘Lawson LA Blouin RA Smith RB 1981Surg Neurol1981,16,1:1
202,4,4-trichlorobiphenyl increase STAT5 transcriptional activity显示文摘 Roe AL Blouin RA 2001Mol Carcinog2001,30,4:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费